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A B S T R A C T
Pancreatic cancer is predicted to be the second leading cause of cancer-related death by 2025. The best che-
motherapy only extends survival by an average of 18 weeks. The extensive fibrotic stroma surrounding the
tumor curbs therapeutic options as chemotherapy drugs cannot freely penetrate the tumor. RNA interference
(RNAi) has emerged as a promising approach to revolutionize cancer treatment. Small interfering RNA (siRNA)
can be designed to inhibit the expression of any gene which is important given the high degree of genetic
heterogeneity present in pancreatic tumors. Despite the potential of siRNA therapies, there are hurdles limiting
their clinical application such as poor transport across biological barriers, limited cellular uptake, degradation,
and rapid clearance. Nanotechnology can address these challenges. In fact, the past few decades have seen the
conceptualization, design, pre-clinical testing and recent clinical approval of a RNAi nanodrug to treat disease. In
this review, we comment on the current state of play of clinical trials evaluating siRNA nanodrugs and review
pre-clinical studies investigating the efficacy of siRNA therapeutics in pancreatic cancer. We assess the phy-
siological barriers unique to pancreatic cancer that need to be considered when designing and testing new
nanomedicines for this disease.
1. Introduction
Pancreatic ductal adenocarcinoma [referred to as pancreatic cancer
(PC)] is the fourth leading cause of cancer-related deaths in developed
countries with a dismal five-year survival rate of 8% [1]. PC has seen
little improvement in patient survival in the past four decades and is
projected to be the second leading cause of cancer mortality by 2025
[2]. Unfortunately, PC is often diagnosed at an advanced stage with the
development of metastatic spread at diagnosis [3]. Surgical resection
improves patient survival, but only 15–20% of patients have surgically
resectable tumors and long-term survival after surgery remains poor
[3,4]. Tragically, our best chemotherapy treatments only improve life
by an average of 8–16 weeks [4] and there is an urgent need to develop
more effective treatments.
One of the defining histopathological features of PC is the highly
fibrotic stroma that can constitute more than 80% of the tumor mass
[5,6] (Fig. 1). Importantly, a higher stromal content in human PC pa-
tients is associated with poor survival outcome [7,8]. This desmoplastic
reaction results in the deposition of an unusually dense network of
extracellular matrix proteins around tumor elements, which compresses
and distorts tumor blood vessels and acts as a physical barrier to che-
motherapy drug delivery [9–11]. In addition, this abnormal vasculature
drives hypoxia in PC tumors which promotes the development of che-
moresistance [9]. This dense fibrosis is produced by cancer associated
pancreatic stellate cells (PSCs) which are normally in a quiescent form
in healthy pancreas but are recruited by PC cells where a cross-talk
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mechanism fuels the aggressiveness of PC [9,12–16]. Indeed, PSCs are
now considered key cellular therapeutic targets in order to reprogram
the fibrosis in PC and also to block the bi-directional pro-tumorigenic
signaling that exists with cancer cells. It is thus imperative to consider
both the tumor and its surrounding stroma when designing novel
therapeutic strategies for PC. In this regard, there has been intense
research to try and harness the power of the RNA interference (RNAi)
gene silencing mechanism in both tumor cells and stromal cells to
therapeutically inhibit tumor-promoting genes. RNAi molecules in-
cluding small interfering RNA (siRNA) can be designed to silence the
expression of genes whose proteins are considered difficult to inhibit
using chemical agents or monoclonal antibodies. This technology offers
the opportunity to target a cocktail of tumor-promoting genes in dif-
ferent cell types present in the tumor microenvironment. However,
despite the potential of siRNA-based therapies, the challenge of delivery
and release of siRNA into cells are obstacles which hinder its full clin-
ical potential. To overcome these hurdles, nanotechnology represents a
promising way to deliver siRNA to cells. In fact, an increasing number
of studies have investigated the use of non-viral nanoparticles to deliver
siRNA to PC tumors in pre-clinical mouse models [17]. In this review,
we discuss the prospects and challenges of utilising nanoparticles as a
delivery vehicle for siRNA in PC (Fig. 1). Furthermore, we comment on
the physiological barriers unique to PC that need to be addressed when
designing new nanotherapeutic drugs for this devastating disease.
2. Targeting the “undruggable” using gene silencing drugs
In the past decade, research has identified a wealth of novel cancer-
related genes that promote tumor progression, metastases and treat-
ment resistance in both PC tumor and surrounding stromal cells [18].
Many of these genes and proteins are considered ‘undruggable’ since
they do not have pharmacological inhibitors or are difficult to inhibit
using small drug molecules due to: 1) a lack of well-defined ligand
binding sites; or 2) close amino acid sequence homology with other
proteins which limits target selectivity. The potential to selectively in-
hibit these genes using RNAi-nanomedicines represents a highly pro-
mising strategy to halt tumor progression and improve overall patient
survival.
RNAi is a naturally occurring gene silencing mechanism in
mammalian cells which can be used to inhibit therapeutic gene targets
[19,20]. In contrast to pharmacological inhibitors that are often not
specific to their target gene, RNAi molecules such as siRNA or short
hairpin RNA (shRNA) offer the advantage of greater selectivity due to
their mechanism of action [21]. siRNA consists of double-stranded RNA
of approximately 21–23 base pairs with 2–3 nucleotide overhangs at the
3′ end. It binds to the RNA-induced silencing complex (RISC) located in
the cell cytoplasm, where the guide strand of siRNA directs the RISC
protein complex to recognize and cleave target mRNA between nu-
cleotides 10 and 11 upstream of the 5′ end of siRNA, resulting in its
cleavage and degradation [21–23] (Fig. 2). Once cleavage has taken
place the RISC-siRNA can be recycled for further cleavage reactions.
Thus, the ability of siRNA to silence the expression of any gene has led
to a major effort to harness its power for the treatment of many types of
human disease such as cancer.
Despite the promise of siRNA-therapeutics for cancer treatment,
delivery of siRNA into cells is a major obstacle preventing its use in the
clinic. This is due to (1) large size of siRNA (approx. 13.5 kDa): and its
negative charge; (2) naked (unmodified) siRNA is prone to degradation
by serum proteins in the blood, and can be rapidly taken up and
eliminated from the body by the reticuloendothelial system [24]. As
mentioned above, the dense fibrotic stroma and vascular barriers pre-
sent in PC tumors add a layer of extra complexity for effective siRNA
delivery to PC cells. To overcome these hurdles, non-viral nanoparticles
are being used to package and deliver siRNA to cells [17].
3. Nanoparticles as a delivery vehicle for siRNA
Non-viral nanoparticles can act as delivery vehicles for a host of
different therapeutic drugs [25]. Indeed, nano-based medicines are al-
ready in clinical use for the treatment of cancer. Nanoparticles can be
designed with physical properties which make them attractive delivery
vehicles for drugs including: 1) sub-micrometer size; 2) high surface-to-
volume ratio; 3) potential to chemically modify their surface with
tumor cell targeting moieties or attach polyethylene glycol (PEG) which
helps provide stability as well as increase blood circulation time; and 4)
versatility to package and deliver proteins, small molecule inhibitors,
chemotherapy drugs or nucleic acids [26]. The last 20 years has seen
the design and synthesis of many different types of non-viral
Fig. 1. Unique clinical challenges of pancreatic
cancer therapeutics give rise to the potential of
RNAi-nanoparticles. The cross-talk between pan-
creatic stellate cells and tumor cells promotes the
progression of pancreatic cancer, and the potential of
RNAi-nanoparticles to specifically target either cell
type can inhibit this cross-talk. Furthermore, by se-
lectively targeting pancreatic stellate cells, RNAi-na-
noparticles can reduce the fibrosis produced by these
cells to normalize tumor vasculature and improve
drug delivery. In addition, the heterogeneity and
chemoresistance of tumor cells can be overcome by
inhibiting multiple targets with RNAi-nanoparticles,
as well as the potential for a personalized therapeutic
strategy to inhibit genes specific to a patient's tumor.
This human pancreatic cancer tissue specimen was
collected by surgical removal as part of the
Australian Pancreatic Cancer Genome Initiative
(APGI) and as approved by the UNSW Human
Research Ethics Committee (HC180973). The histo-
logical tissue micrograph is a typical human pan-
creatic adenocarcinoma paraffin-embedded sample
stained for Sirius red and methyl green. Sirius red
staining for collagen (A) demonstrates the dense fi-
brotic stroma that surrounds and compresses tumor
elements (B), shown in green.
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nanoparticles made from a variety of compounds including polymers,
lipids, aptamers and inorganic materials to deliver siRNA to cells [27].
To provide nanoparticles the best opportunity to penetrate and ac-
cumulate within solid tumors, they are typically synthesized in a size
range of 10–200 nm. This size enables nanoparticles to take full ad-
vantage of the ‘enhanced permeability and retention effect’ (EPR)
which occurs due to the poorly formed and often leaky disorganized
vessels within a solid tumor [28]. Nanoparticles larger than 10 nm have
difficulty in penetrating healthy tissue due to well-developed and
functional vessels which possess tight gap junctions [29]. In a solid
tumor the presence of leaky vessels with dysregulated large gap junc-
tions combined with poor lymphatic drainage allow nanoparticles to
accumulate and become trapped within the tumor [30]. This phe-
nomenon is referred to as ‘passive tumor targeting’. Although efficiency
of nanoparticle delivery via the EPR effect is debated, a recent study in
humans [31] showed for the first time that a chemotherapy drug
(Camptothecin) conjugated to a biocompatible co-polymer nanoparticle
comprising of cyclodextrin and polyethylene glycol (PEG) with a size of
20–30 nm (CRLX101, Cerulean Pharma Inc) was able to penetrate into
human gastric tumors which were collected via endoscopy. Notably, no
drug-nanoparticle was detected in adjacent non-tumor tissue implying
that the nanoparticle was able to passively accumulate into the tumor
due to the EPR effect. This is encouraging, and as scientists we need to
be cautious that we utilize the best mouse tumor models which mimic
the heterogeneity of the altered vasculature and microenvironment that
contribute to the EPR effect. Importantly, all current nanomedicines
used in the clinic passively target tumors. Examples include, Doxil®
(liposomal doxorubicin) which was the first FDA approved
nanomedicine to enter the clinic and Abraxane™ (albumin bound pa-
clitaxel) which is used in first line therapy for PC [32]. Another nano-
medicine clinically approved for second line treatment of metastatic PC
is Onivyde which comprises of the topoisomerase I inhibitor irinotecan
encapsulated in a liposomal nanoparticle decorated with polyethylene
glycol (PEG) which helps increase stability and circulation time in the
bloodstream [33]. While these two agents have been successful in de-
livering chemotherapeutics to pancreatic tumors, there are several ad-
ditional challenges that need to be considered when designing nano-
particle systems for therapeutic siRNA delivery.
An important physical requirement that requires careful con-
sideration when designing nanoparticles for siRNA delivery is its ability
to release siRNA into the cytosol. Once a nanoparticle-siRNA complex
reaches a tumor, it must be internalized by the cells and escape from
early endosomes to allow siRNA to engage RISC [34] (Fig. 2). Recently,
it has come to attention that escape of siRNA from endosomes is not a
trivial process but a key determinant for effective gene silencing ac-
tivity [35,36]. Nanoparticles carrying siRNA interact with the cell
membrane of cancer cells to trigger endocytosis. The size, shape, charge
and surface chemistry of a nanoparticle greatly influence the me-
chanism(s) of endocytosis [reviewed in detail elsewhere [37]]. Once
internalized, nanoparticle-siRNA trapped in early endosomes undergo
intracellular trafficking which is a dynamic process [38]. Early endo-
somes transport their cargo to different subcellular destinations. Some
of the cargo will also be recycled to the plasma membrane via recycling
endosomes and exocytosed from the cell, while other early endosomes
will mature into late endosomes which integrate with lysosomes to form
endolysosomal vesicles [38]. Hydrolytic enzymes within these vesicles
Fig. 2. Nanoparticle-siRNA-induced gene silen-
cing. Nanoparticles containing siRNA undergo en-
docytosis at the plasma membrane to enter the cy-
toplasm (1). Once in the cell, the nanoparticle-siRNA
complexes are trapped in early endosomes (2). There
is evidence to suggest that siRNA can escape from
early endosomes into the cytoplasm. The early en-
dosomes then mature into late endosomes and fuse
with lysosomes, causing the endolysosomal vesicles
to swell and eventually burst, releasing the siRNA
into the cytoplasm – a process known as endosomal
escape (3). The free siRNA is then processed, and a
single strand of siRNA binds to the RNA-induced si-
lencing complex (RISC) where it can bind to a com-
plementary mRNA sequence (4). The mRNA se-
quence is then cleaved into short fragments, thus
specifically silencing the target gene which decreases
its protein expression (5). Abbreviations: siRNA:
short interfering RNA.
J. Kokkinos, et al. Biomaterials 240 (2020) 119742
3
will degrade the remaining cargo [38]. It has been suggested that the
buffering capacity of nanoparticles with a positive surface charge ac-
tivate proton pumps which increase osmotic pressure inside early en-
dosomes resulting in swelling and rupture (termed, proton-sponge ef-
fect) [39]. Another possible mechanism for siRNA endosomal escape is
cationic lipids present in nanoparticles fuse with anionic lipids in the
plasma membrane of endosomes causing membrane disruption [40].
However, despite these routes for siRNA escape, a study by Gilleron
et al. [41] demonstrated that lipid nanoparticles (LNPs) which belong
to a class of highly advanced nanoparticle delivery systems for siRNA
have low efficiency (approx. 1–2%) for escape from early endosomes.
Another study showed that up to 70% of LNPs internalized into cells are
exocytosed by late endosomes/endolysosomes after 24 h [42]. These
studies highlight the importance of understanding how different na-
noparticle systems are not only internalized into cells but how effec-
tively they release their cargo to achieve potent gene silencing activity.
This is an area of active research with the design and synthesis of next
generation polymeric, lipid, inorganic or hybrid nanoparticles [43–45].
Below are some recent examples demonstrating the potential of these
nanoparticles for effective siRNA uptake and release into cells.
Lipid and polymeric-based nanoparticles: Lipid-based nanoparticles
(LNPs) which contain pH-responsive ionizable cationic lipids have been
demonstrated to be highly efficient for the delivery and release of
siRNA into cells. These lipids are amphiphilic and can efficiently self-
assemble with siRNA via an electrostatic interaction under acidic con-
ditions [46]. Importantly, these lipids have a near neutral surface
charge when complexed to siRNA at physiological pH 7 and display a
low toxicity and immunogenic profile. However, when the lipids are
exposed to a low pH acidic environment present in early/late endo-
somes they become positively charged which encourages nanoparticle-
siRNA disassembly and endosomal membrane disruption to allow
siRNA to escape into the cytoplasm. Incorporation of these lipids into
nanoparticles has seen a marked improvement in siRNA gene silencing
activity. One of the earliest studies reported by Lee et al. [47] showed
that LNPs which contained the ionizable lipid 2,2-dilinoleyl-4-(2-di-
methylaminoethyl)- [1,3]-dioxolane (DLin-KC2-DMA) were able to
potently silence the expression of the androgen receptor in orthotopic
prostate tumors in mice. This led to a marked decrease in prostate
specific antigen levels in the blood. Jyotsana et al. [48] demonstrated
LNPs which incorporated the ionizable lipid DLin-MC3-DMA were able
to deliver siRNA targeted against the fusion oncogene BCR-ABL with
high efficiency to human Chronic Myeloid Leukemia (CML) cells both in
vitro and in vivo. These cells are notoriously difficult to transfect using
standard cationic nanoparticles thus highlighting the advantages of
incorporating ionizable lipids into nanoparticles.
Polymeric nanoparticles comprised of ionizable polymers have also
shown great promise as siRNA delivery vehicles. For example, 7C1 io-
nizable polymeric nanoparticles preferentially target the endothelium
and can safely deliver very low amounts of siRNA with potent gene
silencing activity in vivo. Dahlman et al. [49] reported that 7C1 nano-
particles containing 0.1 mg/kg siRNA could silence a target gene ex-
pressed in the lung endothelium by 90% in mice. Notably, 7C1 nano-
particles could deliver up to 5 different siRNAs to achieve potent multi-
gene silencing in vivo. Recently, the clinical potential of 7C1 nano-
particles was further highlighted by potent gene silencing in the en-
dothelium of multiple organs in non-human primates without inducing
any toxicity or immune response [50].
Inorganic-based nanoparticles: Carbon nanotubes and gold nano-
particles have been used as highly effective delivery vehicles for siRNA.
Cao et al. [51] recently developed a novel single-wall carbon nanotube
(SWCNT) which could package and deliver both a chemotherapy drug
and siRNA simultaneously to tumor cells. The surface of the SWCNT
was modified with polyethyleneimine (PEI) covalently linked with be-
taine to produce a pH responsive SWCNT. Moreover, the cell pene-
trating peptide BR2 was conjugated to the surface to encourage cell
uptake. The multifunctional nanoparticle was able to be internalized
into tumor cells and effectively release siRNA from the endosomes to-
gether with a chemotherapy drug to significantly inhibit tumor growth
in mice. Perche et al. [52] synthesized gold nanoparticles functiona-
lized with PEG to deliver siRNA to HeLa cells. Like most gold nano-
particles coated with PEG, endosomal escape of siRNA was limited.
However, Perche et al. [52] conjugated hydroxychloroquine, a clini-
cally approved drug with endosomal disrupting properties, to the sur-
face of the gold nanoparticles. This improved the release of siRNA from
early endosomes which correlated to a two-fold increase in gene si-
lencing activity.
Hybrid-based nanoparticles: Hybrid nanoparticles are also showing
promise for the delivery of siRNA to cells. Qiu et al. [53] recently de-
veloped a highly novel hybrid nanoparticle system which comprised of
two cationic polymers, 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP) and 1,2-dioleoyl-sn-glycero-3-phoshoethanolamine (DOPE) as
well as cholesterol to self-assemble siRNA into a cationic nanocomplex.
These nanoparticles are prone to rapid exocytosis and degradation once
internalized into cells via the endosome-lysosomal degradation
pathway [54]. To alter the intracellular trafficking of the nanoparticles,
the authors decorated their surface with an endoplasmic reticulum (ER)
membrane isolated from cancer cells. This led to a change in the mode
of cellular uptake for the nanoparticles as well as intracellular traf-
ficking via the endosome-Golgi-ER pathway. Importantly, this allowed
the nanoparticle-siRNA complex to escape lysosomal degradation and
resulted in a pronounced increase in gene silencing activity in vitro and
in vivo.
4. Current state of play of gene silencing nanodrugs in the clinic
Despite the numerous challenges, the past decade has seen an in-
creased number of RNAi-based nanotherapeutics progress from pre-
clinical studies to clinical trial. In particular, the development of LNPs
has led to the first FDA approved RNAi therapeutic (Patisiran, ONPA-
TTRO®) [55]. In brief, LNPs are non-viral nanoparticles with a size of
approximately 80–100 nm and consist of a mixture of cationic, ioniz-
able and PEGylated lipids [56]. These nanoparticles have properties
that make them highly desirable for use in the clinic, namely, low
surface charge which minimizes toxicity and immunogenicity, high
drug encapsulation efficiency and reproducible methodology that al-
lows for large scale clinical grade synthesis. LNPs were used to en-
capsulate siRNA targeting wild type and mutant transthyretin (TTR), a
disease-causing gene for hereditary transthyretin (TTR)-mediated
amyloidosis autosomal dominant disorder (Table 1). Treatment options
for this genetic disease were limited. Patisiran® delivered intravenously
at 0.3 mg/kg once every three weeks was able to potently silence the
expression of TTR in liver hepatocytes (target cell) leading to a sig-
nificant reduction of TTR protein in the blood and tissue [57,58]. This
correlated with a marked improvement in disease symptoms. The ap-
proval of Patisiran® as a RNAi therapeutic for human disease provides a
much-needed boost of confidence for RNAi researchers and nano-
technologists and demonstrates proof-of-principle that the RNAi gene
silencing mechanism can be harnessed to therapeutically inhibit an
undruggable gene to achieve a positive clinical outcome.
CALAA-01, produced by Calando Pharmaceuticals, is a targeted
polymer nanoparticle-siRNA system which was evaluated in clinical
trial for the treatment of cancer. This was the first RNAi therapeutic to
be administered to cancer patients. CALAA-01 contained a linear cy-
clodextrin based polymer which could self-assemble siRNA via a simple
mixing process as well as a hydrophilic polymer [(adamantane poly-
ethylene glycol (AD-PEG)] to provide nanoparticle stability in blood. A
cancer cell targeting peptide was conjugated to its surface, designed to
bind the human transferrin receptor and undergo receptor-mediated
endocytosis. Importantly, the investigators were able to show that the
nanoparticle-siRNA, when administered to human cancer patients, was
able to penetrate solid tumors and silence the expression of its target
gene (ribonucleotide reductase M2, RRM2) [19,59,60]. However, the
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phase 1 clinical trial was terminated when several patients experienced
dose limiting toxicities including diarrhea, fever, and fatigue [60]. The
cause was most likely due to nanoparticle instability and breakdown of
the individual components in the blood. Toxicity was thought to have
arisen from the transferrin targeting peptide. This study highlights the
complexity of nanoparticle systems when comprised of multiple com-
ponents and the potential to breakdown when exposed to circulation in
blood. Despite the termination of this potential RNAi therapeutic, im-
portant lessons can be taken from this highly valuable study to produce
‘next generation’ nanoparticle systems for the delivery of siRNA to solid
tumors. To date, more than 20 RNAi-based nanomedicines have un-
dergone or are currently in clinical trials for treatment of multiple
cancer types (Table 2).
5. Gene silencing nanomedicines for the treatment of pancreatic
cancer
There are an increasing number of studies reporting the develop-
ment and use of RNAi therapeutics for PC. In 2007, Pirollo et al. [61]
demonstrated the potential of liposomes containing human epidermal
growth factor receptor 2 (HER-2) siRNA with a transferrin receptor
antibody attached to its surface. Following intravenous injection into
mice with subcutaneous PC tumors, HER-2 protein expression was re-
duced along with a marked decrease in tumor growth [61]. Other
studies have also investigated a range of different nanoparticle systems
packaged with siRNA against tumor promoting genes including, CUX-1
(cut like homebox 1), VEGF (vascular endothelial growth factor) and
EPAS1 (endothelial PAS domain protein 1) in vivo (summarised in
Table 3) [62–66]. Notably, several studies have highlighted the ability
of RNAi nanomedicines to selectively target and inhibit the un-
druggable mutant KRAS gene in PC tumors. This gene is present in over
90% of PC tumors [67]. The high degree of selectivity for RNAi was
showcased when shRNA was able to inhibit the mutant KRAS gene
without effecting the expression of wild-type KRAS in mouse PC tumors
[68]. This led to a significant reduction in tumor growth without any
toxicity to non-tumor cells.
In addition, some studies have developed multi-functional nano-
particles capable of dual siRNA and chemotherapy drug delivery. A
recent study used liposomes to deliver both gemcitabine and siRNA
targeting RRM2 to subcutaneous PC tumors [69]. Given that RRM2 can
promote gemcitabine resistance, knockdown of RRM2 in tumors with
high expression of RRM2 led to a further reduction in tumor growth
with liposomal gemcitabine delivery [69]. Similarly, Yin et al. [70]
developed a gold nanorod system to deliver both KRAS siRNA and
doxorubicin to subcutaneous PANC1 tumors. Importantly, these nano-
particles were activated by near-infrared light (655 nm) both in vitro
and in vivo which stimulated the nanoparticles to release the siRNA and
doxorubicin [70]. Another study published by the same group used
light-activated 2D graphene oxide nanosheets for dual delivery of
siRNA targeting both histone deacetylase 1 (HDAC1) and KRAS in
subcutaneous pancreatic tumors [71]. While these light-activated na-
noparticles appear promising, it remains to be investigated whether
these nanoparticles will be effective in an orthotopic tumor setting and
whether they can be applied to metastatic disease. Another example of
a multifunctional nanoparticle was developed by Yoo et al. [72], uti-
lising a magnetic nanoparticle to both monitor treatment with MRI
imaging and delivery of siRNA targeting PD-L1 in subcutaneous pan-
creatic tumors. An elegant study published by Boehnke et al. [73] de-
tailed the design and in vivo testing of a novel theranostic nanoparticle
for both diagnostic and siRNA delivery capabilities. This nanoparticle
consisted of a liposomal core with layer-by-layer assembly of a bio-
sensing peptide, a targeting peptide and siRNA encapsulation. Im-
pressively, the biosensing peptide is cleaved by proteases expressed in
the tumor microenvironment and releases a synthetic reporter that can
be detected in urine, as demonstrated in three different mouse models
of pancreatic, ovarian and colorectal cancer [73]. Collectively, these
studies provided important proof-of-concept for the use of siRNA
therapeutics in the treatment of PC, however many of the preclinical
models utilized subcutaneous PC tumors in mice. Unfortunately, these
tumors lack many of the drug delivery challenges associated with
pancreatic tumors in the clinical setting i.e. presence of an extensive
fibrotic stroma, dysfunctional or compressed blood vessels and a
functional immune system. Therefore, in recent times, a stronger em-
phasis has been placed on examining the therapeutic potential of RNAi
nanomedicines using more clinically relevant PC models.
One of the earliest studies using an orthotopic PC mouse model to
examine a siRNA-nanotherapeutic was performed by Zhao et al. [74].
This model involves the surgical implantation of human or mouse PC
cells into the tail of the pancreas. The nanoparticles were comprised of a
cationic hydrophobic co-polymer core that encapsulated the che-
motherapy drug gemcitabine (used in the first line treatment of PC) and
electrostatically bound siRNA targeting hypoxia inducible factor-1α
(HIF-1α) on its surface [74]. The nanoparticles were also coated in a
PEGylated lipid bilayer to help minimize the interaction with serum
proteins and maximize circulation time. Systemic administration of the
RNAi-drug induced potent HIF-1α knockdown at the protein level as
well as a marked reduction in tumor volume [74]. Our research pro-
gram showed that polymeric star-shaped nanoparticles consisting of
poly(dimethylaminoethyl methacrylate) (PDMAEMA) and poly(ethy-
lene glycol) methacrylate (POEGMA, a homologue of PEG) were able to
rapidly self-assemble siRNA and deliver it with high efficiency to or-
thotopic PC mouse tumors to silence the expression of an undruggable
gene (βIII-tubulin) which plays an important role in regulating PC
growth and chemosensitivity [75]. A study by Mahajan et al. [76] de-
monstrated profound anti-tumor effects of a novel theranostic nano-
particle delivering siRNA targeted against Polo-like kinase 1 (PLK1) a
mitotic kinase known to be highly expressed in PC cells and is a major
regulator of the cell cycle [77]. The significance of this study was
highlighted by using both the PC syngeneic and genetically engineered
mouse model (GEMM). Both models have a PC tumor
Table 1
Current clinical status of RNAi therapeutics (non-cancer).
Disease Name Target Delivery System Delivery route Trial Status Clinical Trial Identifier
METAVIR F3-4 ND-L02-s0201 HSP47 SNALP I.V. Phase Ib/II-ongoing NCT02227459 (2014)




Phase I/II, recruiting NCT02956317 (2017)
Transthyretin amyloidosis Patisiran/ALN-
TTR02
TTR SNALP I.V. FDA- and European Commission-
approved
NCT01960348 (2018)
CVD, HCL PRO-040201 ApoB SNALP I.V. Phase I, terminated NCT00927459 (2009)
CVD, Elevated LDL-C ALN-PCS02 PCSK9 SNALP I.V. *Phase I NCT01437059 (2011)
Ebola infection TKM-100201 Viral RNA Lipid-based NP I.V. Phase I, terminated NCT01518881 (2011)
Abbreviations: METAVIR F3-4, moderate to extensive hepatic fibrosis; CVD, cardiovascular disease; HCL, hypercholesterolemia; LDL-C, low-density lipoprotein-
cholesterol; HSP47, heat shock protein 47; TGF- β1, transforming growth factor beta 1; Cox-2, cyclooxygenase-2; TTR, transthyretin; ApoB, apolipoprotein B; PCSK9,
pro-protein convertase subtilisin/kexin type 9; SNALP, stable nucleic acid lipid particles; I.V., intravenous; NP, nanoparticle; *, No update posted to date.
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microenvironment that closely mimics the human setting [76]. Im-
portantly, both models also have a fully functional immune system. A
recent study demonstrated an anti-tumor and metastatic effect of in-
organic gold nanoparticles delivering nerve growth factor (NGF) siRNA
to a patient-derived xenograft PC tumor in mice [78]. Taken together,
these studies clearly provide strong rationale for the continued devel-
opment of gene-silencing nanomedicines for the treatment of PC.
RNAi nanotherapeutics also has potential use for targeting the non-
tumor cell population within the PC tumor microenvironment.
Pancreatic Stellate Cells (PSCs) are the key cell type responsible for
producing the dense fibrotic stroma in PC tumors [5,6]. Gold nano-
particles with PEGylated lipids were recently designed to package all-
trans retinoic acid (ATRA) and siRNA targeting heat shock protein-47
(HSP47) [79]. ATRA, an active metabolite of vitamin A, and siRNA
against HSP47 are both known to induce PSC quiescence [80–82].
Notably, systemic administration of the nanoparticle into mice with
orthotopic PC tumors (established via injection of cancer cells and PSCs
into the pancreas) resulted in a significant remodelling of the fibrotic
tissue. This led to increased chemotherapy drug penetration and in-
hibited PC tumor growth and metastases. This study demonstrates the
potential of combining RNAi therapeutics with chemotherapy drugs to
target multiple cell types within the tumor microenvironment. The
potential to target PSCs and the stroma with siRNA nanoparticles will
be further discussed below.
6. Challenges and opportunities in pancreatic cancer
As mentioned throughout this review, one of the most defining and
unique features of PC is the highly fibrotic stroma that surrounds and
compresses tumor elements [5,6]. We now have a clear understanding
that the stroma is a key player in promoting PC progression, che-
moresistance and metastasis [9]. Thus, it is critical to address the role of
the stroma when designing new nanotherapeutics for PC. Fig. 3 details
key recommendations to be considered when designing and testing
nanoparticles for PC treatment.
Stroma-rich solid tumors such as PC generate high levels of solid
and fluid stress as well as dense extracellular matrix [83]. Indeed, leaky
tumor blood vessels result in increased interstitial fluid pressure (IFP),
and this is further exacerbated by the compressed lymphatic vessels
that do not allow adequate fluid drainage [84]. Accordingly, tumor IFP
becomes comparable to the microvascular pressure thus alleviating the
pressure gradient between the blood vessels and the tumor [84]. Re-
markably, in a GEMM of PC, IFP was demonstrated to be almost 10-fold
higher in PC tumors compared to normal pancreas [10]. As a result,
passive diffusion becomes the main transvascular transport mechanism
for nanoparticles into the tumor. Given that the rate of diffusion is in-
versely proportional to the size of the nanoparticle, larger nanoparticles
are hindered from diffusing and penetrating solid tumors [85]. Con-
sistent with this research, the majority of successful RNAi-nanoparticles
tested in orthotopic PC mouse models are within a size range of
17–60 nm [74,75,78,79]. The importance of nanoparticle size to PC
tumor penetration was nicely highlighted in a study by Cabral et al.
[86], that compared micelle-packaged chemotherapy penetrance into
mouse colorectal tumors with penetrance into more fibrotic orthotopic
PC tumors in mice. Good accumulation and efficacy was demonstrated
in chemotherapy-loaded micelles ranging in size from 30 to 100 nm in
the colorectal cancer mouse model, whereas only the 30 nm micelles
had superior accumulation and anti-tumor effects compared to larger
micelles (70 and 100 nm) in the orthotopic PC mouse model [86].
Independent of fluid flow, diffusion of large nanoparticles can also
be inhibited by physical interactions with the dense extracellular pro-
tein matrix in the stroma [85]. Using computational modeling to un-
derstand the transport of gold-nanoparticles through a hydrogel col-
lagen matrix, a recent study demonstrated greater diffusion of smaller
nanoparticles (15 nm) compared to larger nanoparticles (100 nm)
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diffusion rate, the smaller nanoparticles displayed a greater frequency
of collisions with the extracellular matrix proteins compared to the
larger nanoparticles [87]. Taken together, these studies clearly illus-
trate that a fine balance needs to be achieved when determining the
optimal size of nanoparticles for stromal rich tumors such as PC.
Nonetheless, based on the studies described above, it can at least be
hypothesized that nanoparticles within a size ranging from 20 to 50 nm
would be optimal for penetrating PC tumors. However, if the model
proposed by Sykes et al. [87] is relevant in an in vivo setting and is
applicable across a broad range of nanoparticle systems, we could
predict that increased collisions of smaller nanoparticles with the ex-
tracellular matrix might be a useful strategy when designing nano-
particles to selectively target the stroma of PC. This approach can be
combined with the addition of targeting moieties specific to PSCs for
targeted delivery, as elegantly demonstrated in a recent study [79].
Further studies are warranted to test this hypothesis in clinically re-
levant and stroma-rich PC models.
In addition to size, the surface charge of nanoparticles needs to be
considered when designing them for siRNA delivery to PC tumors. The
charge of a nanoparticle can significantly affect its diffusion through a
tumor due to potential electrostatic interactions with components of the
extracellular protein matrix. Adsorption of serum proteins is also an-
other challenge nanoparticles encounter. Nanoparticles with a high
positive surface charge are susceptible to strong binding with a host of
different serum proteins including, apolipoproteins, fibronectins and
immunoglobulins [88]. The protein corona formed on the surface of
nanoparticles can significantly influence their size and charge which
can affect cellular uptake [88]. It is accepted that positively charged
nanoparticles are more efficient at targeting tumor angiogenic vascu-
lature, compared to neutral or negatively charged particles [89]. This
was understood to be the result of irregular and sluggish blood flow that
increases the frequency of interactions between positively charged
particles and anionic sites on angiogenic tissue of tumor vessels [89].
The protein corona formed on these nanoparticles may have con-
tributed to their altered blood flow. In contrast, another study elegantly
demonstrated that neutrally-charged nanoparticles diffuse faster
through the extracellular matrix due to less electrostatic interactions
with the matrix proteins [90]. Nonetheless, siRNA delivery vehicles
often require a slight positive charge to electrostatically bind negatively
charged siRNA. Since PC is characterized by a dense network of ex-
tracellular matrix in the stroma, it can be concluded that nanoparticles
designed for PC should have a close-to-neutral charge.
The size, charge and surface chemistry of nanoparticles can also
influence how they interact with other cells in different tissues and can
thus affect their toxicity. Nanoparticles must demonstrate a favorable
pharmacokinetic profile to maximize their therapeutic potential but
must also be adequately cleared from the circulation to limit toxicity
[25]. Given the renal system only allows clearance of particles less than
8 nm, most nanoparticles are cleared by the reticuloendothelial and
hepatobiliary systems [91]. This involves opsonization where the na-
noparticle is coated by nonspecific proteins to allow phagocytosis to
occur [92]. The opsonized nanoparticle is then cleared by macrophages
in the liver and spleen. Modification of surface chemistry including
PEGylation of nanoparticles can greatly reduce opsonization and pha-
gocytic clearance [93]. There is also evidence that both size and charge
of nanoparticles can influence their interaction with the re-
ticuloendothelial system and hence affect their clearance [94–97]. In
addition, surface charge can significantly affect the interaction of na-
noparticles with the plasma membrane and intracellular components of
cells. In general, positively charged particles are believed to be more
cytotoxic than neutral or anionic nanoparticles [96]. However, we must
remain cautious of applying these general recommendations across all
nanoparticle systems, reinforcing the need for robust pharmacokinetic
and toxicology in vivo analysis of new nanoparticles as part of the pre-
clinical development pipeline. In addition to nanoparticle-mediated
toxicity, extra considerations need to be made to limit the toxicity and
off-target effects of siRNA. However, recent advances in siRNA tech-
nology have mostly overcome these challenges by improving the se-
quence selection and chemical modification of siRNA [98,99]. The ef-
fects of “on-target” silencing of genes in normal non-tumor tissue must
also be considered, so emphasis should be placed on selecting genes
that are upregulated specifically in tumor tissue. Furthermore, nano-
medicine offers the opportunity to actively or passively target tumor
cells and can thus overcome this issue.
Overall, all of the above physiochemical properties need to be
considered when designing new nanoparticles for PC. In particular, the
characteristics of the fibrotic stroma and dense extracellular matrix
pose unique drug delivery challenges for PC. However, while the
stroma has been classically thought of as a barrier to conventional drug
delivery, we propose that the stroma can be considered an opportunity
to be harnessed by nanomedicine. In recent years, the concept of
stromal reprogramming in PC has become a popular way to improve
Table 3
Pre-clinical studies of RNAi nanoparticles in pancreatic cancer.
Delivery vehicle siRNA target Size (nm) PC model Delivery route Citations
Liposome HER-2 100 PANC1 s.c tumors I.V. [61]
PEI-complex CUX-1 – CAPAN1 s.c tumors I.T. [63]
Calcium phosphate polymer VEGF 100 BxPC3 s.c tumors I.V. [62]
PEG-poly-lysine KRAS – PANC1 s.c tumors I.V. [64,65]
PEI-complex EPAS1 160–22 BxPC3 s.c tumors NR [66]
Polylysine co-polymer HIF-1α 60 PANC1 s.c and orthotopic tumors I.V. [74]
Gold nanorods KRAS 22 × 47 PANC1 s.c tumors NR [70]
PEG-cationic lipoplex Survivin 225 Hs766 T s.c tumors I.V. [112]
Superparama-gnetic iron oxide nanoparticles PLK1 123 Syngeneic orthotopic and GEMM I.V. [76]
STAR-PEG βIII-Tubulin 38 Orthotopic MiaPaCa2 and HPAF-II tumors I.V. [75]
PEG-dendrimers Nur 77/TR3 200 PANC1 s.c tumors I.V. [113]
Gold nanoclusters NGF 17 PANC1 s.c and orthotopic models, and orthotopic PDX I.V. [78]
Polyester based vectors KRAS 100 MiaPaCa2 s.c tumors P.T. [114]
Graphene oxide nanoparticles VEGF 100–250 S180 s.c tumors I.V. [115]
Lipid nanoparticle RRM2 – PANC1 s.c tumors I.V. [116]
Gold nanoparticles HSP47 41 PANC1/PSC orthotopic tumors I.V. [79]
Magnetic nanocarrier PD-L1 23 Pan 02 s.c tumors I.V. [72]
Peptide-based nanoparticle KRAS 55 KPC-1 s.c tumors I.V. [117]
Abbreviations: PEI, polyethylenimine; PEG, polyethylene glycol; HER2, human epidermal growth factor receptor 2; CUX-1, cut like homeobox 1; VEGF, vascular
endothelial growth factor; EPAS1, endothelial PAS domain-containing protein 1; HIF-1a, hypoxia-inducible factor 1α; PD-L1, programmed death-ligand 1; PLK-1,
polo-like kinase 1; NGF, nerve growth factor RRM2, ribonucleotide reductase M2; HSP47, heat shock protein 47; s.c, subcutaneous; GEMM, genetically engineered
mouse model; I.V., intravenous; I.T., intratumoral; NR, not reported; P.T., peritumoral.
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chemotherapy drug delivery and halt tumor progression. Importantly,
nano-based gene-silencing drugs have the potential to silence ther-
apeutic targets specific to PSCs in an attempt to normalise or reprogram
the stroma. In fact, there are several different aspects of PSC biology
that can be targeted by gene-therapy nano drugs. One aspect of PSC
biology that has recently been targeted by an siRNA-nanomedicine used
an inorganic gold nanoparticle to deliver HSP47 siRNA to pancreatic
tumors in vivo [79]. HSP47 is a collagen-specific molecular chaperone
involved in the maturation of collagen [100]. As discussed above,
knockdown of HSP47 sensitized PC tumors to gemcitabine, a standard
of care for PC, which was believed to occur due to a reduction in col-
lagen levels, normalization of tumor vasculature and improved drug
delivery [79]. Another approach to reprogram the PC stroma is to in-
activate PSCs into their natural quiescent state. PSC quiescence can be
induced by blocking the vitamin D receptor which is highly expressed
in PSCs. Indeed, treatment with the vitamin D receptor ligand calci-
potriol has been shown to reprogram the stroma in a mouse model of PC
to improve gemcitabine efficacy [101], and is currently under in-
vestigation in clinical trial [102]. There is thus potential here for a
nanomedicine-siRNA to be developed to target the vitamin D receptor
or other key targets involved in PSC activation. In addition, a recent
study elegantly demonstrated that perlecan is a novel therapeutic target
intricately involved in the crosstalk between PSCs and cancer cells
[103]. Genetic depletion of perlecan in the stroma of PC markedly
improved the efficacy of gemcitabine and Abraxane™ in a PC mouse
model [103]. There are currently limited pharmacological inhibitors for
perlecan, suggesting the potential for a nanomedicine-siRNA approach
to therapeutically target this important aspect of PSC biology.
7. Concluding remarks
The potential to silence any tumor promoting gene with RNAi-na-
notherapeutics holds promise for PC treatment. This has been shown by
several advanced pre-clinical studies that have demonstrated significant
anti-tumor, chemosensitizing and anti-metastatic effects with siRNA-
nanotherapeutics. However, before these promising findings can be
translated to the clinic, we need to examine these nanomedicines in pre-
clinical models that accurately reflect the biology of human PC. This
includes orthotopic PC mouse models with an intact and functional fi-
brotic stroma, genetically engineered mouse models with a functional
immune system as well as complex 3D in vitro and ex vivo models of the
disease. For example, multicellular culture of tumor spheroids in
Fig. 3. Recommendations for the design and pre-clinical testing of RNAi-nanoparticles in the context of pancreatic cancer. Abbreviations: ECM:
Extracellular matrix; PC: Pancreatic cancer.
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microfluidics devices can recapitulate many microenvironmental cues
such as raised IFP, and can thus be a highly useful tool in the pre-
clinical development of siRNA-nanotherapeutics [104,105]. If these
models can be designed with high throughput capabilities, nano-
particles with different siRNA targets can be tested on patient tumor
samples to guide a personalized medicine program. These models, used
in parallel with clinically relevant in vivo models, can inform the design
of new nanoparticles. We now know that a “one-size-fits-all” approach
can no longer be used when designing nanoparticles for cancer treat-
ment. Rather, it is necessary to address the unique pathophysiology of
PC, and in particular the fibrotic stroma which presents several barriers
for nanoparticle delivery. On the chemistry front, strong consideration
needs to be given for developing methodologies that can produce large
scale and reproducible amounts of clinical grade nanomaterials. If we
are to revolutionize the treatment of PC, it is imperative to build
stronger collaborations between chemists, biologists and clinicians, as
this will ultimately pave the way for a personalized medicine strategy
for PC using siRNA-nanoparticles to inhibit target genes that are unique
to a patient's tumor.
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